Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm

A patient with a rare, aggressive, blastic plasmacytoid dendritic-cell neoplasm had tumor cells overexpressing BCL2 and had a response with a durable remission to venetoclax, a BCL2 inhibitor.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2018-10, Vol.379 (15), p.1479-1481
Hauptverfasser:	Agha, Mounzer E, Monaghan, Sara A, Swerdlow, Steven H
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biopsy Bone marrow Bortezomib - therapeutic use Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Dendritic cells Dendritic Cells - pathology Female Hematologic Neoplasms - drug therapy Hematologic Neoplasms - pathology Humans Medical prognosis Middle Aged Positron Emission Tomography Computed Tomography Remission Simvastatin - therapeutic use Skin Neoplasms - drug therapy Skin Neoplasms - pathology Sulfonamides - therapeutic use Tomography Tumor cells Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A patient with a rare, aggressive, blastic plasmacytoid dendritic-cell neoplasm had tumor cells overexpressing BCL2 and had a response with a durable remission to venetoclax, a BCL2 inhibitor.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc1808354